Mapmygenome Acquires Vancouver-Based dnaPower Inc.
The acquisition expands Mapmygenome's North American footprint in DNA and microbiome testing services.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust that larger health-testing companies provide better, more affordable services to patients?
Mapmygenome has officially completed its acquisition of dnaPower Inc., a Vancouver-based firm founded in 2008. This move scales Mapmygenome's precision health, longevity, and microbiome testing operations across Canada and the United States.
Why it matters
The acquisition allows Mapmygenome to integrate its global research pipeline with dnaPower's established consumer reach. This creates a centralized testing platform designed to streamline diagnostic services throughout the North American market.
The integration utilizes CAP-accredited and ISO-certified protocols at a new Vancouver processing hub. This infrastructure supports a combined testing platform that standardizes DNA and microbiome analysis for North American clients.
The players
Mapmygenome
Mapmygenome is a global molecular diagnostics company that operates CAP-accredited clinical laboratories focused on personalized health.
dnaPower Inc.
dnaPower Inc. is a Vancouver-based company that provides genetic and microbiome testing services to help consumers understand their health potential.
The details
By folding dnaPower into its existing organizational structure, Mapmygenome solidifies its presence in the region following the 2025 acquisition of Microbiome Insights. The merger combines the research and development capabilities of Mapmygenome with the consumer-facing infrastructure previously developed by dnaPower.
Timeline
dnaPower was established in 2008.
Mapmygenome acquired Microbiome Insights in 2025.
The acquisition of dnaPower Inc. was completed on October 21, 2026.
The Tech Race
This acquisition reflects the broader industry trend of rapid consolidation as established molecular diagnostic firms absorb smaller, consumer-focused genetics companies. By merging infrastructure, these companies aim to dominate the precision health market through scale and technical efficiency.
Consumers in North America can expect more integrated access to precision health data through the combined testing platform. The standardization of lab protocols is intended to improve the reliability and speed of results for DNA and microbiome testing services.
The takeaway
The integration of dnaPower into Mapmygenome suggests a move toward more streamlined, scalable health testing solutions for international consumers. Customers should monitor their service portals for updates as the companies complete their operational alignment.
Further reading
Learn more about the latest industry developments in Biotech.
Live Poll
Do you trust that larger health-testing companies provide better, more affordable services to patients?
